Protalix BioTherapeutics (PLX) Net Cash Flow (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Net Cash Flow of $26.4 million for Q1 2026, up 9078.91% year-over-year from $287594.0 in Q1 2025, and up 2381.02% quarter-over-quarter from $1.1 million in Q4 2025.
Protalix BioTherapeutics (PLX) Net Cash Flow (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at $26.4 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 9078.91% year-over-year to $26.4 million; the TTM figure through Mar 2026 stood at $21.7 million (up 71.29% YoY), while the FY2025 annual figure was -$5.0 million, down 29.08% from the prior year.
- Net Cash Flow for Q1 2026 stood at $26.4 million, up from $1.1 million in the prior quarter.
- The five-year high for Net Cash Flow was $26.4 million in Q1 2026, with the low at -$27.8 million in Q3 2023.
- The 5-year median for Net Cash Flow is -$294000.0 (2025), against an average of $1.2 million.
- The sharpest annual moves came in 2022 and 2026: Net Cash Flow tumbled 1483.83% in 2022, then soared 9078.91% in 2026.
- Protalix BioTherapeutics' Net Cash Flow stood at $6.4 million in 2022, then tumbled by 49.31% to $3.3 million in 2023, then sank by 336.8% to -$7.7 million in 2024, then jumped by 113.81% to $1.1 million in 2025, then surged by 2381.02% to $26.4 million in 2026.
- Business Quant data shows PLX's Net Cash Flow at $26.4 million in Q1 2026, $1.1 million in Q4 2025, and -$4.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn | -14.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.04 Mn |
| Jun 30, 2026 | -14.04 Mn |
| Mar 31, 2026 | 26.40 Mn |
| Mar 31, 2026 | 26.40 Mn |
| Dec 31, 2025 | 1.06 Mn |
| Dec 31, 2025 | 1.06 Mn |
| Sep 30, 2025 | -4.24 Mn |
| Sep 30, 2025 | -4.24 Mn |
| Jun 30, 2025 | -1.57 Mn |
| Jun 30, 2025 | -1.57 Mn |
| Mar 31, 2025 | -294,000.00 |
| Mar 31, 2025 | -294,000.00 |
| Dec 31, 2024 | -7.70 Mn |
| Dec 31, 2024 | -7.70 Mn |
| Sep 30, 2024 | 24.43 Mn |
| Sep 30, 2024 | 24.43 Mn |
| Jun 30, 2024 | -3.79 Mn |
| Jun 30, 2024 | -3.79 Mn |
| Mar 31, 2024 | 3.58 Mn |
| Mar 31, 2024 | 3.58 Mn |